Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],50,2528,DB01381,Ginkgo biloba
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],182,2529,DB01381,Ginkgo biloba
,22414318,encapsulation efficiency,The encapsulation efficiency of the total ginkgo terpenes (GT) in the optimal formulation was 78.84±2.06% with a loading dose of 11.90±0.31mg/150mg PELGE.,Co-encapsulation and sustained-release of four components in ginkgo terpenes from injectable PELGE nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22414318/),%,78.84,15850,DB01381,Ginkgo biloba
,22414318,zeta potential,The particles exhibited a spherical shape with a mean diameter of 123.3±44.0nm and zeta potential of -30.86±2.49mV.,Co-encapsulation and sustained-release of four components in ginkgo terpenes from injectable PELGE nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22414318/),mv,-,15851,DB01381,Ginkgo biloba
,22414318,zeta potential,The particles exhibited a spherical shape with a mean diameter of 123.3±44.0nm and zeta potential of -30.86±2.49mV.,Co-encapsulation and sustained-release of four components in ginkgo terpenes from injectable PELGE nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22414318/),mv,30.86,15852,DB01381,Ginkgo biloba
,23213741,Tmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),h,0.444,50510,DB01381,Ginkgo biloba
,23213741,Tmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),h,1,50511,DB01381,Ginkgo biloba
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],0.764,50512,DB01381,Ginkgo biloba
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],3.024,50513,DB01381,Ginkgo biloba
,23213741,Cmax,"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[mg] / [l],11.013,50514,DB01381,Ginkgo biloba
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],1.007,50515,DB01381,Ginkgo biloba
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],3.644,50516,DB01381,Ginkgo biloba
,23213741,AUC(0-1),"After intravenous drips of 0.62, 2.07 and 10.35 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were as follows: Tmax were 0.444, 1, 1 h; Cmax were 0.764, 3.024, 11.013 mg/L; AUC(0-1) were 1.007, 3.644, 16.646 mg x h/Lo.",[Study on pharmacokinetics of ginkgolide B injection in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23213741/),[h·mg] / [lo],16.646,50517,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of the free form of the prototype ginkgolides, the absolute bioavailabilities of GA and GB were 34.8 and 5.2% in the fasted dogs, respectively, which significantly increased to an average of 78.6 and 17.0%, respectively, in the fed dogs.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,34.8,55217,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of the free form of the prototype ginkgolides, the absolute bioavailabilities of GA and GB were 34.8 and 5.2% in the fasted dogs, respectively, which significantly increased to an average of 78.6 and 17.0%, respectively, in the fed dogs.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,5.2,55218,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of the free form of the prototype ginkgolides, the absolute bioavailabilities of GA and GB were 34.8 and 5.2% in the fasted dogs, respectively, which significantly increased to an average of 78.6 and 17.0%, respectively, in the fed dogs.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,78.6,55219,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of the free form of the prototype ginkgolides, the absolute bioavailabilities of GA and GB were 34.8 and 5.2% in the fasted dogs, respectively, which significantly increased to an average of 78.6 and 17.0%, respectively, in the fed dogs.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,17.0,55220,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of acidified total lactones, the absolute bioavailabilities of GA and GB were 7.5 and 14.5% in the fed dogs, and the percentages declined to 4.1 and 3.7% in the fasted dogs, respectively.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,7.5,55221,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of acidified total lactones, the absolute bioavailabilities of GA and GB were 7.5 and 14.5% in the fed dogs, and the percentages declined to 4.1 and 3.7% in the fasted dogs, respectively.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,14.5,55222,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of acidified total lactones, the absolute bioavailabilities of GA and GB were 7.5 and 14.5% in the fed dogs, and the percentages declined to 4.1 and 3.7% in the fasted dogs, respectively.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,4.1,55223,DB01381,Ginkgo biloba
,29516538,absolute bioavailabilities,"In terms of acidified total lactones, the absolute bioavailabilities of GA and GB were 7.5 and 14.5% in the fed dogs, and the percentages declined to 4.1 and 3.7% in the fasted dogs, respectively.","The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29516538/),%,3.7,55224,DB01381,Ginkgo biloba
,20486074,maximum plasma concentrations,"A single dose of 600 mg/kg EGb 761® resulted in maximum plasma concentrations of 176, 341, and 183 ng/mL for quercetin, kaempferol, and isorhamnetin/tamarixetin, respectively and in maximum brain concentrations of 291 ng/g protein for kaempferol and 161 ng/g protein for isorhamnetin/tamarixetin.",Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486074/),[ng] / [ml],176,55411,DB01381,Ginkgo biloba
,20486074,maximum plasma concentrations,"A single dose of 600 mg/kg EGb 761® resulted in maximum plasma concentrations of 176, 341, and 183 ng/mL for quercetin, kaempferol, and isorhamnetin/tamarixetin, respectively and in maximum brain concentrations of 291 ng/g protein for kaempferol and 161 ng/g protein for isorhamnetin/tamarixetin.",Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486074/),[ng] / [ml],341,55412,DB01381,Ginkgo biloba
,20486074,maximum plasma concentrations,"A single dose of 600 mg/kg EGb 761® resulted in maximum plasma concentrations of 176, 341, and 183 ng/mL for quercetin, kaempferol, and isorhamnetin/tamarixetin, respectively and in maximum brain concentrations of 291 ng/g protein for kaempferol and 161 ng/g protein for isorhamnetin/tamarixetin.",Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486074/),[ng] / [ml],183,55413,DB01381,Ginkgo biloba
,20486074,maximum brain concentrations,"A single dose of 600 mg/kg EGb 761® resulted in maximum plasma concentrations of 176, 341, and 183 ng/mL for quercetin, kaempferol, and isorhamnetin/tamarixetin, respectively and in maximum brain concentrations of 291 ng/g protein for kaempferol and 161 ng/g protein for isorhamnetin/tamarixetin.",Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486074/),[ng] / [g],291,55414,DB01381,Ginkgo biloba
,20486074,maximum brain concentrations,"A single dose of 600 mg/kg EGb 761® resulted in maximum plasma concentrations of 176, 341, and 183 ng/mL for quercetin, kaempferol, and isorhamnetin/tamarixetin, respectively and in maximum brain concentrations of 291 ng/g protein for kaempferol and 161 ng/g protein for isorhamnetin/tamarixetin.",Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486074/),[ng] / [g],161,55415,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,245,60592,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,211,60593,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,264,60594,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,203,60595,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,333,60596,DB01381,Ginkgo biloba
,26116277,bioavailabilities,"The bioavailabilities of quercetin, kaempferol, isorhmnetin, ginkgolide A, ginkgolide B and ginkgolide C from proliposomes relative to the control were 245%, 211%, 264%, 203%, 333%, and 294%, respectively.","Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: Formulation optimization, characterization, oral bioavailability and tissue distribution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116277/),%,294,60597,DB01381,Ginkgo biloba
,10193211,maximum concentrations,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),[ng] / [ml],68,62293,DB01381,Ginkgo biloba
,10193211,maximum concentrations,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),[ng] / [ml],40,62294,DB01381,Ginkgo biloba
,10193211,maximum concentrations,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),[ng] / [ml],159,62295,DB01381,Ginkgo biloba
,10193211,half-lives,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),h,1.7,62296,DB01381,Ginkgo biloba
,10193211,half-lives,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),h,2.0,62297,DB01381,Ginkgo biloba
,10193211,half-lives,"For the lowest dose maximum concentrations were 68, 40 and 159 ng/ml and half-lives 1.7, 2.0 and 2.2 h for ginkgolide A, B and bilobalide, respectively.",Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),h,2.2,62298,DB01381,Ginkgo biloba
,10193211,Clearance,Clearance values ranged from 24.2 to 37.6 ml/min/kg.,Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193211/),[ml] / [kg·min],24.2 to 37.6,62299,DB01381,Ginkgo biloba
,26010697,Extraction recoveries,"Extraction recoveries in rat plasma for ginkgolides A, B, C and bilobalide ranged from 75.6% to 89.0%.","Simultaneous determination of ginkgolides A, B, C and bilobalide by LC-MS/MS and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26010697/),%,75.6,74903,DB01381,Ginkgo biloba
,26010697,Extraction recoveries,"Extraction recoveries in rat plasma for ginkgolides A, B, C and bilobalide ranged from 75.6% to 89.0%.","Simultaneous determination of ginkgolides A, B, C and bilobalide by LC-MS/MS and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26010697/),%,89.0,74904,DB01381,Ginkgo biloba
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],24.4,77527,DB01381,Ginkgo biloba
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],22.7,77528,DB01381,Ginkgo biloba
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],25.0,77529,DB01381,Ginkgo biloba
,27318642,flow rate,Then the analytes were successfully separated by running gradient elution with the mobile phase consisting of 0.1% formic acid in water and methanol at a flow rate of 0.6mL/min.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),[ml] / [min],0.6,91312,DB01381,Ginkgo biloba
,27318642,extraction recoveries,The mean extraction recoveries of the analytes were within 69.82%-103.5% and the matrix were within 82.8%-110.0%.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),%,69,91313,DB01381,Ginkgo biloba
,27318642,extraction recoveries,The mean extraction recoveries of the analytes were within 69.82%-103.5% and the matrix were within 82.8%-110.0%.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),%,82,91314,DB01381,Ginkgo biloba
,24747521,total run time,The total run time was 12.0 min.,Development of a dynamic multiple reaction monitoring method for determination of digoxin and six active components of Ginkgo biloba leaf extract in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24747521/),min,12.0,92997,DB01381,Ginkgo biloba
,33361030,absolute oral bioavailability,"Oral administration of IAsp-N-Glc exhibited a low absolute oral bioavailability (1.83±0.09%), and 59.63±6.29% of IAsp-N-Glc was excreted in feces.",The bioavailability and excretion of an antitussive compound IAsp-N-Glc in rats by validated UPLC-MS/MS methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33361030/),%,1.83,95031,DB01381,Ginkgo biloba
,33361030,absolute oral bioavailability,"Oral administration of IAsp-N-Glc exhibited a low absolute oral bioavailability (1.83±0.09%), and 59.63±6.29% of IAsp-N-Glc was excreted in feces.",The bioavailability and excretion of an antitussive compound IAsp-N-Glc in rats by validated UPLC-MS/MS methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33361030/),%,59.63,95032,DB01381,Ginkgo biloba
,29103463,half-life,"GA, GB, and GK showed a constant half-life approximately 2.7, 3.4, and 1.2 h, respectively, which were consistent for the forms at three dose levels (0.3, 1.0, and 3.0 mg·kg-1) and after a consecutive injection of GDLI for 7 days (1.0 mg·kg-1).","Pharmacokinetics of the prototype and hydrolyzed carboxylic forms of ginkgolides A, B, and K administered as a ginkgo diterpene lactones meglumine injection in beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29103463/),h,2.7,97518,DB01381,Ginkgo biloba
,29103463,half-life,"GA, GB, and GK showed a constant half-life approximately 2.7, 3.4, and 1.2 h, respectively, which were consistent for the forms at three dose levels (0.3, 1.0, and 3.0 mg·kg-1) and after a consecutive injection of GDLI for 7 days (1.0 mg·kg-1).","Pharmacokinetics of the prototype and hydrolyzed carboxylic forms of ginkgolides A, B, and K administered as a ginkgo diterpene lactones meglumine injection in beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29103463/),h,3.4,97519,DB01381,Ginkgo biloba
,29103463,half-life,"GA, GB, and GK showed a constant half-life approximately 2.7, 3.4, and 1.2 h, respectively, which were consistent for the forms at three dose levels (0.3, 1.0, and 3.0 mg·kg-1) and after a consecutive injection of GDLI for 7 days (1.0 mg·kg-1).","Pharmacokinetics of the prototype and hydrolyzed carboxylic forms of ginkgolides A, B, and K administered as a ginkgo diterpene lactones meglumine injection in beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29103463/),h,1.2,97520,DB01381,Ginkgo biloba
,25367786,recovery,The mean recovery of the analytes ranged from 68.11% to 84.42%.,Simultaneous determination by UPLC-MS/MS of seven bioactive compounds in rat plasma after oral administration of Ginkgo biloba tablets: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25367786/),%,68.11,103368,DB01381,Ginkgo biloba
,25367786,recovery,The mean recovery of the analytes ranged from 68.11% to 84.42%.,Simultaneous determination by UPLC-MS/MS of seven bioactive compounds in rat plasma after oral administration of Ginkgo biloba tablets: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25367786/),%,84.42,103369,DB01381,Ginkgo biloba
,12845387,AUC(0- infinity ),No significant difference between treatments was observed with respect to AUC(0- infinity ) (digoxin alone: 21.0 +/- 8.6 [ng/mL] x h; digoxin + GB: 25.6 +/- 13.2 [ng/mL] x h).,Impact of ginkgo biloba on the pharmacokinetics of digoxin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845387/),[ng] / [h·ml]],21.0,103486,DB01381,Ginkgo biloba
,12845387,AUC(0- infinity ),No significant difference between treatments was observed with respect to AUC(0- infinity ) (digoxin alone: 21.0 +/- 8.6 [ng/mL] x h; digoxin + GB: 25.6 +/- 13.2 [ng/mL] x h).,Impact of ginkgo biloba on the pharmacokinetics of digoxin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845387/),[ng] / [h·ml]],25.6,103487,DB01381,Ginkgo biloba
,22876684,Tmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),h,0.083,105932,DB01381,Ginkgo biloba
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],422.312,105933,DB01381,Ginkgo biloba
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],1608.467,105934,DB01381,Ginkgo biloba
,22876684,Cmax,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[μg] / [l],1987.036,105935,DB01381,Ginkgo biloba
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],533.833,105936,DB01381,Ginkgo biloba
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],1786.029,105937,DB01381,Ginkgo biloba
,22876684,AUC0-1,"After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L. Ginkgolide",[Study on the pharmacokinetics of ginkgolide B for injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22876684/),[h·μg] / [l],1943.44,105938,DB01381,Ginkgo biloba
,2947082,absorption,The absorption of the radiolabelled Ginkgo biloba extract was at least 60%.,"[Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat]. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2947082/),%,60,106826,DB01381,Ginkgo biloba
,2947082,biological half-life,"The pharmacokinetics of the drug, based on blood specific activity data versus time course, were characteristic of a two-compartment model with an apparent first order phase and a biological half-life of approximatively 4.5 h.","[Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2947082/),h,4.5,106827,DB01381,Ginkgo biloba
,7631288,bioavailability coefficients (FAUC),"When given orally, while fasting, the extents of bioavailability are high, as shown by bioavailability coefficients (FAUC) mean (+/- SD) values equal to 0.80 (+/- 0.09), 0.88 (+/- 0.21) and 0.79 (+/- 0.30) for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),,0.80,115074,DB01381,Ginkgo biloba
,7631288,bioavailability coefficients (FAUC),"When given orally, while fasting, the extents of bioavailability are high, as shown by bioavailability coefficients (FAUC) mean (+/- SD) values equal to 0.80 (+/- 0.09), 0.88 (+/- 0.21) and 0.79 (+/- 0.30) for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),,0.88,115075,DB01381,Ginkgo biloba
,7631288,bioavailability coefficients (FAUC),"When given orally, while fasting, the extents of bioavailability are high, as shown by bioavailability coefficients (FAUC) mean (+/- SD) values equal to 0.80 (+/- 0.09), 0.88 (+/- 0.21) and 0.79 (+/- 0.30) for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),,0.79,115076,DB01381,Ginkgo biloba
,7631288,elimination half-lives (T1/2Z),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,4.50,115077,DB01381,Ginkgo biloba
,7631288,elimination half-lives (T1/2Z),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,10.57,115078,DB01381,Ginkgo biloba
,7631288,elimination half-lives (T1/2Z),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,3.21,115079,DB01381,Ginkgo biloba
,7631288,mean residence times (MRT),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,5.86,115080,DB01381,Ginkgo biloba
,7631288,mean residence times (MRT),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,11.25,115081,DB01381,Ginkgo biloba
,7631288,mean residence times (MRT),"For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.",[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631288/),h,4.89,115082,DB01381,Ginkgo biloba
,19922896,B,Bleeding time was determined before dosing (0 hour) and at 5 and 24 hours after dosing.,"Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,0,120342,DB01381,Ginkgo biloba
,19922896,T(max),Median (range) T(max) of ticlopidine was 1.5 (0.5-2.0) hours in both groups.,"Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,1.5,120343,DB01381,Ginkgo biloba
,19922896,t((1/2)),"The mean (SD) t((1/2)) of ticlopidine in the combined fixed-dose formulation and the concomitant administration groups was 19.5 (3.4) and 19.0 (3.3) hours after study drug administration, respectively.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,19.5,120344,DB01381,Ginkgo biloba
,19922896,t((1/2)),"The mean (SD) t((1/2)) of ticlopidine in the combined fixed-dose formulation and the concomitant administration groups was 19.5 (3.4) and 19.0 (3.3) hours after study drug administration, respectively.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,19.0,120345,DB01381,Ginkgo biloba
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,4.5,120346,DB01381,Ginkgo biloba
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,5.4,120347,DB01381,Ginkgo biloba
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,4.4,120348,DB01381,Ginkgo biloba
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,5.1,120349,DB01381,Ginkgo biloba
>,19922896,bleeding times,"Five subjects (3 in the combined fixed-dose formulation group and 2 in the concomitant administration group) had bleeding times >8 minutes, but this was not considered to be clinically significant.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,8,120350,DB01381,Ginkgo biloba
,17202649,half-life,Intravenously administered GB was eliminated in a biphasic manner with a prominent initial phase (half-life of 0.3 h) followed by a slower terminal phase (half-life of 1.5 h).,Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),h,0.3,120494,DB01381,Ginkgo biloba
,17202649,half-life,Intravenously administered GB was eliminated in a biphasic manner with a prominent initial phase (half-life of 0.3 h) followed by a slower terminal phase (half-life of 1.5 h).,Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),h,1.5,120495,DB01381,Ginkgo biloba
,17202649,AUC(0-tau),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[min·μg] / [ml],53.7,120496,DB01381,Ginkgo biloba
,17202649,AUC(0-tau),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[min·μg] / [ml],165.5,120497,DB01381,Ginkgo biloba
,17202649,AUC(0-tau),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[min·μg] / [ml],649.7,120498,DB01381,Ginkgo biloba
,17202649,CL,"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[l] / [kg·min],0.07,120499,DB01381,Ginkgo biloba
,17202649,CL,"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[l] / [kg·min],0.05,120500,DB01381,Ginkgo biloba
,17202649,V(C),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[l] / [kg],2.27,120501,DB01381,Ginkgo biloba
,17202649,V(C),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[l] / [kg],3.27,120502,DB01381,Ginkgo biloba
,17202649,V(C),"After i.v. 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53.7, 165.5 and 649.7; CL (l/min/kg): 0.07, 0.07 and 0.05; V(C) (l/kg): 2.27, 3.27 and 2.76, respectively.",Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202649/),[l] / [kg],2.76,120503,DB01381,Ginkgo biloba
,18295555,flow rate,"Chromatographic separation was achieved on a 5 microm Shiseido C8 column (150 mm x 2.0 mm i.d., particle size 5 microm) with a mobile phase consisting of methanol/ 6 mM ammonium acetate (60/40, v/v) at a flow rate of 0.3 ml/min.","Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295555/),[ml] / [min],0.3,128201,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],189,138845,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],200,138846,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],201,138847,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],127,138848,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],126,138849,DB01381,Ginkgo biloba
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],131,138850,DB01381,Ginkgo biloba
,28809433,AUC from 0 to 48 h,"In plasma, the mean AUC from 0 to 48 h was 14.12, 12.59, 23.75, 1.51 h μg/ml for GLJ and 5.34 h μg/ml for GLA, GLB, GLC, GLJ and BLL, respectively.",Pharmacokinetic and ocular microdialysis study of oral ginkgo biloba extract in rabbits by UPLC-MS/MS determination. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28809433/),[h·μg] / [ml],14.12,145437,DB01381,Ginkgo biloba
,28809433,AUC from 0 to 48 h,"In plasma, the mean AUC from 0 to 48 h was 14.12, 12.59, 23.75, 1.51 h μg/ml for GLJ and 5.34 h μg/ml for GLA, GLB, GLC, GLJ and BLL, respectively.",Pharmacokinetic and ocular microdialysis study of oral ginkgo biloba extract in rabbits by UPLC-MS/MS determination. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28809433/),[h·μg] / [ml],12.59,145438,DB01381,Ginkgo biloba
,28809433,AUC from 0 to 48 h,"In plasma, the mean AUC from 0 to 48 h was 14.12, 12.59, 23.75, 1.51 h μg/ml for GLJ and 5.34 h μg/ml for GLA, GLB, GLC, GLJ and BLL, respectively.",Pharmacokinetic and ocular microdialysis study of oral ginkgo biloba extract in rabbits by UPLC-MS/MS determination. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28809433/),[h·μg] / [ml],23.75,145439,DB01381,Ginkgo biloba
,28809433,AUC from 0 to 48 h,"In plasma, the mean AUC from 0 to 48 h was 14.12, 12.59, 23.75, 1.51 h μg/ml for GLJ and 5.34 h μg/ml for GLA, GLB, GLC, GLJ and BLL, respectively.",Pharmacokinetic and ocular microdialysis study of oral ginkgo biloba extract in rabbits by UPLC-MS/MS determination. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28809433/),[h·μg] / [ml],1.51,145440,DB01381,Ginkgo biloba
,28809433,AUC from 0 to 48 h,"In plasma, the mean AUC from 0 to 48 h was 14.12, 12.59, 23.75, 1.51 h μg/ml for GLJ and 5.34 h μg/ml for GLA, GLB, GLC, GLJ and BLL, respectively.",Pharmacokinetic and ocular microdialysis study of oral ginkgo biloba extract in rabbits by UPLC-MS/MS determination. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28809433/),[h·μg] / [ml],5.34,145441,DB01381,Ginkgo biloba
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],36.84,146673,DB01381,Ginkgo biloba
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],48.68,146674,DB01381,Ginkgo biloba
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],135.82,146675,DB01381,Ginkgo biloba
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],77.28,146676,DB01381,Ginkgo biloba
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,2.62,146677,DB01381,Ginkgo biloba
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,3.32,146678,DB01381,Ginkgo biloba
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,48.2,146679,DB01381,Ginkgo biloba
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,36.7,146680,DB01381,Ginkgo biloba
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,407.10,151490,DB01381,Ginkgo biloba
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,389.20,151491,DB01381,Ginkgo biloba
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,285.08,151492,DB01381,Ginkgo biloba
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,193.10,151493,DB01381,Ginkgo biloba
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],16.1,155061,DB01381,Ginkgo biloba
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.3,155062,DB01381,Ginkgo biloba
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],37.9,155063,DB01381,Ginkgo biloba
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155064,DB01381,Ginkgo biloba
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],63.0,155065,DB01381,Ginkgo biloba
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.3,155066,DB01381,Ginkgo biloba
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155067,DB01381,Ginkgo biloba
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],63.0,155068,DB01381,Ginkgo biloba
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155069,DB01381,Ginkgo biloba
,16326435,AUC,"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[)min·mg(] / [ml],188.1,155070,DB01381,Ginkgo biloba
,16326435,AUC,"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[)min·mg(] / [ml],571.4,155071,DB01381,Ginkgo biloba
,16326435,C(max),"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],1.0,155072,DB01381,Ginkgo biloba
,16326435,C(max),"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],1.8,155073,DB01381,Ginkgo biloba
,16326435,relative oral bioavailability,"The relative oral bioavailability of alcohol calculated as the ratio of AUC(BHR)/AUC(Saline) was 42.5% and 32.9% at 1- and 3-g/kg doses, respectively.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),%,42.5,155074,DB01381,Ginkgo biloba
,16326435,relative oral bioavailability,"The relative oral bioavailability of alcohol calculated as the ratio of AUC(BHR)/AUC(Saline) was 42.5% and 32.9% at 1- and 3-g/kg doses, respectively.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),%,32.9,155075,DB01381,Ginkgo biloba
,12002672,maximum concentration time (Tmax),The maximum concentration time (Tmax) is 2.3 hrs after administration in both treatments.,Pharmacokinetics and bioavailability of a Ginkgo biloba extract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12002672/),h,2.3,161836,DB01381,Ginkgo biloba
,19694739,AUC(0-infinity),"Bupropion mean AUC(0-infinity) value was 1.4 microg.h ml(-1)[95% confidence interval (CI) 1.2, 1.6] prior to G. biloba treatment and 1.2 microg.h ml(-1) (95% CI 1.1, 1.4) after 14 days of treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],1.4,164437,DB01381,Ginkgo biloba
,19694739,AUC(0-infinity),"Bupropion mean AUC(0-infinity) value was 1.4 microg.h ml(-1)[95% confidence interval (CI) 1.2, 1.6] prior to G. biloba treatment and 1.2 microg.h ml(-1) (95% CI 1.1, 1.4) after 14 days of treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],1.2,164438,DB01381,Ginkgo biloba
,19694739,AUC(0-infinity),"Hydroxybupropion mean AUC(0-infinity) value was 8.2 microg.h ml(-1) (95% CI 6.5, 10.4) before G. biloba administration and 8.7 microg.h ml(-1) (95% CI 7.1, 10.6) after treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],8.2,164439,DB01381,Ginkgo biloba
,19694739,AUC(0-infinity),"Hydroxybupropion mean AUC(0-infinity) value was 8.2 microg.h ml(-1) (95% CI 6.5, 10.4) before G. biloba administration and 8.7 microg.h ml(-1) (95% CI 7.1, 10.6) after treatment.",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[h·μg] / [ml],8.7,164440,DB01381,Ginkgo biloba
,19694739,C(max),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[ng] / [ml],221.8,164441,DB01381,Ginkgo biloba
,19694739,C(max),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),[ng] / [ml],272.7,164442,DB01381,Ginkgo biloba
,19694739,t(1/2),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),h,25.0,164443,DB01381,Ginkgo biloba
,19694739,t(1/2),"The C(max) of hydroxybupropion increased from 221.8 ng ml(-1) (95% CI 176.6, 278.6) to 272.7 ng ml(-1) (95% CI 215.0, 345.8) (P = 0.038) and the t(1/2) of hydroxybupropion fell from 25.0 h (95% CI 22.7, 27.5) to 21.9 h (95% CI 19.9, 24.1) (P = 0.000).",Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694739/),h,21.9,164444,DB01381,Ginkgo biloba
,26852855,redispersibility index,"The particle size, polydispersity index, zeta potential, and redispersibility index of freeze-dried GL-NSs were around 286 nm, 0.26, -25.19 mV, and 112%, respectively.",Preparation and Physicochemical and Pharmacokinetic Characterization of Ginkgo Lactone Nanosuspensions for Antiplatelet Aggregation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26852855/),%,112,170142,DB01381,Ginkgo biloba
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.22,180464,DB01381,Ginkgo biloba
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.85,180465,DB01381,Ginkgo biloba
,29953302,AUC(0-t),"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[h·mg] / [l],6.99,180466,DB01381,Ginkgo biloba
,29953302,AUC(0-t),"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[h·mg] / [l],11.94,180467,DB01381,Ginkgo biloba
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.05,180468,DB01381,Ginkgo biloba
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],0.72,180469,DB01381,Ginkgo biloba
,29953302,t1/2,The t1/2 of losartan was prolonged significantly from 3.94 ± 0.62 to 4.75 ± 0.52 h (p < 0.05).,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),h,3.94,180470,DB01381,Ginkgo biloba
,29953302,t1/2,The t1/2 of losartan was prolonged significantly from 3.94 ± 0.62 to 4.75 ± 0.52 h (p < 0.05).,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),h,4.75,180471,DB01381,Ginkgo biloba
,29953302,metabolic stability,The metabolic stability of losartan was increased from 37.4 min to 59.6 min with GLT pretreatment.,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),min,37.4,180472,DB01381,Ginkgo biloba
,29953302,metabolic stability,The metabolic stability of losartan was increased from 37.4 min to 59.6 min with GLT pretreatment.,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),min,59.6,180473,DB01381,Ginkgo biloba
,34329714,half-lives,"The half-lives of ginkgolides A, B, C, and bilobalide (2-3 h) were shorter than quercetin, kaempferol, and isorhamnetin (approximately 20 h).","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),h,2-3,186315,DB01381,Ginkgo biloba
,34329714,half-lives,"The half-lives of ginkgolides A, B, C, and bilobalide (2-3 h) were shorter than quercetin, kaempferol, and isorhamnetin (approximately 20 h).","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),h,20,186316,DB01381,Ginkgo biloba
,34329714,IC50,"In hOATP1B1-HEK293 cells, kaempferol and isorhamnetin contributed to the inhibition of OATP1B1-mediated uptake of 3H-ES with IC50 values of 3.28 ± 1.08 μM and 46.12 ± 5.25 μM, respectively.","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),μM,3.28,186317,DB01381,Ginkgo biloba
,34329714,IC50,"In hOATP1B1-HEK293 cells, kaempferol and isorhamnetin contributed to the inhibition of OATP1B1-mediated uptake of 3H-ES with IC50 values of 3.28 ± 1.08 μM and 46.12 ± 5.25 μM, respectively.","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),μM,46.12,186318,DB01381,Ginkgo biloba
,16023818,C(max),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),[ng] / [ml],43.8,186480,DB01381,Ginkgo biloba
,16023818,T(max),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),h,0.5,186481,DB01381,Ginkgo biloba
,16023818,elimination half-life (t(1/2)),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),h,2.85,186482,DB01381,Ginkgo biloba
,20041430,flow rate,The mobile phase consisted of water + 0.1% acetic acid and methanol 68/32 (v/v) to 49/51 (v/v) at a flow rate of 200 microL/min.,"Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[μl] / [min],200,187410,DB01381,Ginkgo biloba
,20041430,m/z,"Bilobalide, ginkgolide A and ginkgolide B were monitored using the selected-ion monitoring (SIM) mode at m/z of 325, 453 and 423, respectively.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),,325,187411,DB01381,Ginkgo biloba
,20041430,m/z,"Bilobalide, ginkgolide A and ginkgolide B were monitored using the selected-ion monitoring (SIM) mode at m/z of 325, 453 and 423, respectively.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),,453,187412,DB01381,Ginkgo biloba
,20041430,m/z,"Bilobalide, ginkgolide A and ginkgolide B were monitored using the selected-ion monitoring (SIM) mode at m/z of 325, 453 and 423, respectively.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),,423,187413,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],3.53,187414,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],3.62,187415,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],1.38,187416,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],11.68,187417,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],7.36,187418,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],4.18,187419,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],26.85,187420,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],16.44,187421,DB01381,Ginkgo biloba
,20041430,maximum concentrations,"The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761 tablets.","Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20041430/),[ng] / [ml],9.99,187422,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],893.48,194449,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],1123.85,194450,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],314.91,194451,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],505.74,194452,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],2724.97,194453,DB01381,Ginkgo biloba
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],3096.40,194454,DB01381,Ginkgo biloba
,30054600,unbound fractions,The compounds' unbound fractions in plasma were 45-92%.,Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,45-92,196027,DB01381,Ginkgo biloba
>,30054600,Apparent oral bioavailability,"Apparent oral bioavailability of ginkgolides A and B was mostly >100%, while that of ginkgolides C and J was 6-15%.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,100,196028,DB01381,Ginkgo biloba
,30054600,Apparent oral bioavailability,"Apparent oral bioavailability of ginkgolides A and B was mostly >100%, while that of ginkgolides C and J was 6-15%.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),%,6-15,196029,DB01381,Ginkgo biloba
,30054600,Terminal half-lives,"Terminal half-lives of ginkgolides A, B, and C (4-7 h) after dosing ShuXueNing were shorter than their respective values (6-13 h) after dosing YinXing-TongZhi tablet.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,4-7,196030,DB01381,Ginkgo biloba
,30054600,Terminal half-lives,"Terminal half-lives of ginkgolides A, B, and C (4-7 h) after dosing ShuXueNing were shorter than their respective values (6-13 h) after dosing YinXing-TongZhi tablet.",Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,6-13,196031,DB01381,Ginkgo biloba
,30054600,Half-life,Half-life of bilobalide after dosing the tablet was around 5 h.,Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30054600/),h,5,196032,DB01381,Ginkgo biloba
,27490936,flow rate,"Chromatographic separation was achieved on an Eclipse XDB-C18 column (2.1 mm×150 mm, 5 μm) with a mobile phase consisting of methanol/0.1% formic acid water (gradient elution: 0~25 min (77:23)→(60:40), V/V) at a flow rate of 0.3 mL·min-1.","Determination of Ginkgolides A, B, C, J and Bilobalide in Plasma by LC-ESI (-)/MS/MS (QQQ) and its Application to the Pharmacokinetic Study of Ginkgo Biloba Extract in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490936/),[ml] / [min],0.3,196888,DB01381,Ginkgo biloba
less,27490936,half-life of absorption,"The pharmacokinetic properties of BB, GJ, GA, GB and GC were in line with the open 2-compartment model after oral administration of GBE in rats; The pharmacokinetic parameters of various lactones were calculated, and drugs-time curve and the curve fitting diagram of 5 ginkgolides were drew; The absorption and distribution rate of BB, GJ, GA, GB and GC were fast in rats in vivo, and half-life of absorption was less than 3 h.","Determination of Ginkgolides A, B, C, J and Bilobalide in Plasma by LC-ESI (-)/MS/MS (QQQ) and its Application to the Pharmacokinetic Study of Ginkgo Biloba Extract in Rats. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490936/),h,3,196889,DB01381,Ginkgo biloba
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.9,201410,DB01381,Ginkgo biloba
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.5,201411,DB01381,Ginkgo biloba
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],57,201412,DB01381,Ginkgo biloba
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],55,201413,DB01381,Ginkgo biloba
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],32.9,201414,DB01381,Ginkgo biloba
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],31.6,201415,DB01381,Ginkgo biloba
,19299322,area under the plasma concentration-time curve from zero to infinity (AUC(0-)(infinity)),"For extensive metabolizers, the median value for voriconazole area under the plasma concentration-time curve from zero to infinity (AUC(0-)(infinity)) was 5.17 microg.h/mL after administration of voriconazole alone and 4.28 microg.h/mL after voriconazole with Ginkgo biloba (p > 0.05).",Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299322/),[h·μg] / [ml],5.17,202129,DB01381,Ginkgo biloba
,19299322,area under the plasma concentration-time curve from zero to infinity (AUC(0-)(infinity)),"For extensive metabolizers, the median value for voriconazole area under the plasma concentration-time curve from zero to infinity (AUC(0-)(infinity)) was 5.17 microg.h/mL after administration of voriconazole alone and 4.28 microg.h/mL after voriconazole with Ginkgo biloba (p > 0.05).",Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299322/),[h·μg] / [ml],4.28,202130,DB01381,Ginkgo biloba
,26561795,flow rate,The flow rate was set at 0.4 mL/min.,Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[ml] / [min],0.4,205229,DB01381,Ginkgo biloba
,26561795,m/z (Q1/Q3),"Quantitation was performed using multiple reaction monitoring (MRM) in negative ion mode, with the transitions at m/z (Q1/Q3) 423.1/367.1 for GB and m/z 269.3/170.0 for IS.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),,423.1,205230,DB01381,Ginkgo biloba
,26561795,m/z (Q1/Q3),"Quantitation was performed using multiple reaction monitoring (MRM) in negative ion mode, with the transitions at m/z (Q1/Q3) 423.1/367.1 for GB and m/z 269.3/170.0 for IS.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),,367.1,205231,DB01381,Ginkgo biloba
,26561795,m/z,"Quantitation was performed using multiple reaction monitoring (MRM) in negative ion mode, with the transitions at m/z (Q1/Q3) 423.1/367.1 for GB and m/z 269.3/170.0 for IS.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),,269.3,205232,DB01381,Ginkgo biloba
,26561795,m/z,"Quantitation was performed using multiple reaction monitoring (MRM) in negative ion mode, with the transitions at m/z (Q1/Q3) 423.1/367.1 for GB and m/z 269.3/170.0 for IS.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),,170.0,205233,DB01381,Ginkgo biloba
,26561795,Cmax,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [l],309.2,205234,DB01381,Ginkgo biloba
,26561795,Cmax,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [l],192.4,205235,DB01381,Ginkgo biloba
,26561795,Cmax,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [l],66.6,205236,DB01381,Ginkgo biloba
,26561795,AUC,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [h·l],606.7,205237,DB01381,Ginkgo biloba
,26561795,AUC,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [h·l],419.1,205238,DB01381,Ginkgo biloba
,26561795,AUC,"The Cmax values of GB from different formulations in beagle dog plasma were 309.2, 192.4 and 66.6 µg/L, and the AUC values were 606.7, 419.1 and 236.2 µg/L·h, respectively.",Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561795/),[μg] / [h·l],236.2,205239,DB01381,Ginkgo biloba
,32144952,oral bioavailability,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),%,0.06,220984,DB01381,Ginkgo biloba
,32144952,area under the curve,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),[ng] / [h·ml],410.938,220985,DB01381,Ginkgo biloba
,32144952,area under the curve,"Pharmacokinetic studies indicated that the oral bioavailability of AMF was 0.06 ± 0.04%, and the area under the curve of the glucuronidated AMF metabolites (410.938 ± 62.219 ng/ml h) was significantly higher than that of AMF (194.509 ± 16.915 ng/ml h).","Glucuronidation and its effect on the bioactivity of amentoflavone, a biflavonoid from Ginkgo biloba leaves. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32144952/),[ng] / [h·ml],194.509,220986,DB01381,Ginkgo biloba
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.117,232860,DB01381,Ginkgo biloba
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.141,232861,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],93.5,234977,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],86.5,234978,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],91.1,234979,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],89.6,234980,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],29.1,234981,DB01381,Ginkgo biloba
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],29.1,234982,DB01381,Ginkgo biloba
,23421864,k obs,"From the equilibrium of lactone hydrolysis in rat plasma in vitro, the k obs was - 0.0176 min(- 1) and t 1/2 was 39.38 min.",The pharmacokinetics and conversion of the lactone to the carboxylate forms of ginkgolide B in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421864/),1)·min(-,-,244976,DB01381,Ginkgo biloba
,23421864,k obs,"From the equilibrium of lactone hydrolysis in rat plasma in vitro, the k obs was - 0.0176 min(- 1) and t 1/2 was 39.38 min.",The pharmacokinetics and conversion of the lactone to the carboxylate forms of ginkgolide B in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421864/),1)·min(-,0.0176,244977,DB01381,Ginkgo biloba
,23421864,t 1/2,"From the equilibrium of lactone hydrolysis in rat plasma in vitro, the k obs was - 0.0176 min(- 1) and t 1/2 was 39.38 min.",The pharmacokinetics and conversion of the lactone to the carboxylate forms of ginkgolide B in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421864/),min,39.38,244978,DB01381,Ginkgo biloba
,31353500,m/z,"In the process of chromatographic separation, selected reaction monitoring transitions for isoginkgetin and IS were m/z 566.8 → 134.7 and m/z 430.8 → 269.3, respectively.",Validation and application of a novel LC/MS/MS method for the determination of isoginkgetin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353500/),,566.8,259542,DB01381,Ginkgo biloba
,31353500,m/z,"In the process of chromatographic separation, selected reaction monitoring transitions for isoginkgetin and IS were m/z 566.8 → 134.7 and m/z 430.8 → 269.3, respectively.",Validation and application of a novel LC/MS/MS method for the determination of isoginkgetin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353500/),,134.7,259543,DB01381,Ginkgo biloba
,31353500,m/z,"In the process of chromatographic separation, selected reaction monitoring transitions for isoginkgetin and IS were m/z 566.8 → 134.7 and m/z 430.8 → 269.3, respectively.",Validation and application of a novel LC/MS/MS method for the determination of isoginkgetin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353500/),,430.8,259544,DB01381,Ginkgo biloba
,31353500,m/z,"In the process of chromatographic separation, selected reaction monitoring transitions for isoginkgetin and IS were m/z 566.8 → 134.7 and m/z 430.8 → 269.3, respectively.",Validation and application of a novel LC/MS/MS method for the determination of isoginkgetin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353500/),,269.3,259545,DB01381,Ginkgo biloba
,11400198,"maximum plasma concentrations, C(max)","The maximum plasma concentrations, C(max), of total ginkgolides A, B and bilobalide were 85.0 and 181.8 microg/mL for Ginkgoselect and Ginkgoselect Phytosome, respectively.",Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11400198/),[μg] / [ml],85.0,263875,DB01381,Ginkgo biloba
,11400198,"maximum plasma concentrations, C(max)","The maximum plasma concentrations, C(max), of total ginkgolides A, B and bilobalide were 85.0 and 181.8 microg/mL for Ginkgoselect and Ginkgoselect Phytosome, respectively.",Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11400198/),[μg] / [ml],181.8,263876,DB01381,Ginkgo biloba
,11400198,elimination half-life,"In both cases, the mean elimination half-life of each terpene lactone was in the range 120--180 min.",Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11400198/),min,120--180,263877,DB01381,Ginkgo biloba
less,28622621,Extraction recoveries,Extraction recoveries of analytes and IS were less than ±15.0% of nominal concentrations.,Development of an ultra-fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven flavonoids in rat plasma: Application to a comparative pharmacokinetic investigation of Ginkgo biloba extract and single pure ginkgo flavonoids after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28622621/),%,15.0,273655,DB01381,Ginkgo biloba
